Meet Our Proprietary Platform Technologies
Our proprietary platform technologies address critical challengesin therapeutic development and manufacturing. From oligonucleotide synthesis and microbial protein expression to site-specific antibody conjugation, each technology is designed to improve quality, efficiency, scalability, or precision, helping you overcome technical barriers and accelerate progress.
Advances scalable, sustainable oligonucleotide and peptide synthesis through hybrid liquid-phase production.
Enhances stability and yield in antibody conjugates through site-specific conjugation and liner technology.
